- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VYTRUS BIOTECH Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 65,26 | 0,00 % | Morgan Stanley raises Tempus AI price target to $65 from $60 | ||
| ARCELLX | 56,26 | 0,00 % | Arcellx, Inc. - 10-Q, Quarterly Report | ||
| TARSUS PHARMACEUTICALS | 47,140 | -0,46 % | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | ||
| ADMA BIOLOGICS | 21,210 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,295 | 0,00 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
| JANUX THERAPEUTICS | 26,370 | +2,61 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| SPRINGWORKS THERAPEUTICS | 46,205 | +0,01 % | Fast vier Milliarden für Healthcare: Wachstum mit Biopharma: Merck übernimmt SpringWorks Therapeutics | ||
| NUVALENT | 71,58 | 0,00 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results | Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,395 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,640 | 0,00 % | Summit Therapeutics stock rating upgraded to Buy at TD Cowen | ||
| BEAM THERAPEUTICS | 17,240 | 0,00 % | Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for its first quarter that increased from last year and missed the Street estimates.The company's bottom line totaled -$109.27... ► Artikel lesen | |
| BICARA THERAPEUTICS | 13,130 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting... ► Artikel lesen | |
| CG ONCOLOGY | 24,100 | 0,00 % | JPMorgan sets CG Oncology stock overweight, $41 target | ||
| ARCUTIS BIOTHERAPEUTICS | 13,510 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update | Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 28,665 | 0,00 % | Avidity Biosciences, Inc. - 8-K, Current Report |
VYTRUS BIOTECH SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VYTRUS BIOTECH SA finden Sie auf Wallstreet Online.